Form 4: Seres Therapeutics Director Kurt Graves Acquires Stock Options
SEC Form 4 Filing
Director Kurt Graves acquired 64,564 stock options in Seres Therapeutics on July 1, 2024, vesting quarterly over the next year.
Summary
- On July 1, 2024, Kurt Graves, a director of Seres Therapeutics, acquired 64,564 stock options.
- The exercise price of these options is $0.72.
- The options vest in four equal quarterly installments starting October 1, 2024, and ending July 1, 2025, subject to continued service on the Board.
- The expiration date for these options is June 30, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, indicating a neutral sentiment.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
This filing is a routine disclosure of insider transactions, which is common in the biopharmaceutical industry. It provides transparency into the compensation structure for board members.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Kurt Graves acquired stock options. |
| 10/01/2024 | First quarterly vesting date for the stock options. |
| 01/01/2025 | Second quarterly vesting date for the stock options. |
| 04/01/2025 | Third quarterly vesting date for the stock options. |
| 07/01/2025 | Final quarterly vesting date for the stock options, contingent on the timing of the 2025 annual meeting of stockholders. |
| 06/30/2034 | Expiration date of the stock options. |
| 07/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.